<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">7600053</journal-id>
<journal-id journal-id-type="pubmed-jr-id">2780</journal-id>
<journal-id journal-id-type="nlm-ta">Cancer Lett</journal-id>
<journal-id journal-id-type="iso-abbrev">Cancer Lett.</journal-id>
<journal-title-group>
<journal-title>Cancer letters</journal-title>
</journal-title-group>
<issn pub-type="ppub">0304-3835</issn>
<issn pub-type="epub">1872-7980</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30102953</article-id>
<article-id pub-id-type="pmc">6240910</article-id>
<article-id pub-id-type="doi">10.1016/j.canlet.2018.08.006</article-id>
<article-id pub-id-type="manuscript">NIHMS996310</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Fatty acid oxidation: An emerging facet of metabolic transformation in cancer</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Ma</surname>
<given-names>Yibao</given-names>
</name>
<xref ref-type="aff" rid="A1">a</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Temkin</surname>
<given-names>Sarah M.</given-names>
</name>
<xref ref-type="aff" rid="A2">b</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hawkridge</surname>
<given-names>Adam M.</given-names>
</name>
<xref ref-type="aff" rid="A3">c</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Guo</surname>
<given-names>Chunqing</given-names>
</name>
<xref ref-type="aff" rid="A4">d</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Wei</given-names>
</name>
<xref ref-type="aff" rid="A1">a</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Xiang-Yang</given-names>
</name>
<xref ref-type="aff" rid="A4">d</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fang</surname>
<given-names>Xianjun</given-names>
</name>
<xref ref-type="aff" rid="A1">a</xref>
<xref ref-type="corresp" rid="CR1">*</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>a</label>Department of Biochemistry &amp; Molecular Biology, School of Medicine, Virginia Commonwealth University, Richmond, VA, 23298, USA</aff>
<aff id="A2"><label>b</label>Gynecologic Oncology, School of Medicine, Virginia Commonwealth University, Richmond, VA, 23298, USA</aff>
<aff id="A3"><label>c</label>Department of Pharmaceutics, School of Pharmacy, Virginia Commonwealth University, Richmond, VA, 23298, USA</aff>
<aff id="A4"><label>d</label>Human and Molecular Genetics, School of Medicine, Virginia Commonwealth University, Richmond, VA, 23298, USA</aff>
<author-notes>
<corresp id="CR1"><label>*</label>Corresponding author. <email>xianjun.fang@vcuhealth.org</email> (X. Fang).</corresp>
<fn fn-type="COI-statement" id="FN1">
<p id="P30">Conflicts of interest</p>
<p id="P31">The authors declare that they have no conflicts of interest with the contents of this article.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>10</day>
<month>11</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>10</day>
<month>8</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="ppub">
<day>28</day>
<month>10</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>28</day>
<month>10</month>
<year>2019</year>
</pub-date>
<volume>435</volume>
<fpage>92</fpage>
<lpage>100</lpage>
<!--elocation-id from pubmed: 10.1016/j.canlet.2018.08.006-->
<abstract id="ABS1">
<p id="P1">Cancer cells undergo metabolic reprogramming such as enhanced aerobic glycolysis, mutations in the tricarboxylic acid cycle enzymes, and upregulation of <italic>de novo</italic> lipid synthesis and glutaminolysis. These alterations are pivotal to the development and maintenance of the malignant phenotype of cancer cells in unfavorable tumor microenvironment or metastatic sites. Although mitochondrial fatty acid β-oxidation (FAO) is a primary bioenergetic source, it has not been generally recognized as part of the metabolic landscape of cancer. The last few years, however, have seen a dramatic change in the view of cancer relevance of the FAO pathway. Many recent studies have provided significant evidence to support a “lipolytic phenotype” of cancer. FAO, like other well-defined metabolic pathways involved in cancer, is dysregulated in diverse human malignancies. Cancer cells rely on FAO for proliferation, survival, stemness, drug resistance, and metastatic progression. FAO is also reprogrammed in cancer-associated immune and other host cells, which may contribute to immune suppression and tumor-promoting microenvironment. This article reviews and puts into context our current understanding of multi-faceted roles of FAO in oncogenesis as well as anti-cancer therapeutic opportunities posed by the FAO pathway.</p>
</abstract>
<kwd-group>
<kwd>Fatty acid β-oxidation</kwd>
<kwd>Cancer</kwd>
<kwd>Lipolytic phenotype</kwd>
<kwd>ATP</kwd>
<kwd>NADPH</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>